Janssen discontinues development of fulranumab in osteoarthritis pain and returns rights to Amgen.
Janssen Research & Development, LLC announced that it is discontinuing the Phase III development program for fulranumab in osteoarthritis pain. This decision was based on strategic portfolio prioritization and was not based on any emerging safety concerns from the Phase III clinical studies with fulranumab.
Janssen Pharmaceuticals, Inc., an affiliated company, is terminating its licensing agreement with Amgen Inc. for fulranumab and is returning all program rights back to Amgen. Fulranumab is part of an experimental class of non-opioid biological medicines called anti-nerve growth factor compounds. In 2008, Amgen Inc. licensed fulranumab to Ortho-McNeil-Janssen Pharmaceuticals, Inc., now known as Janssen Pharmaceuticals, Inc.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.